The specter of generic rivalry has long loomed above copyright’s iconic drug, Sildenafil, sparking questions about the prospects of connected pharmaceutical portfolios. While initial times saw substantial returns, the patent end has opened the way for less expensive copies, potentially diminishing revenue and creating a genuine risk for investor… Read More